Precision Medicine for Stem Cell Transplantation
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Manchester
About this trial
A study of patients undergoing haematopoietic stem cell transplantation, a procedure in which patients are infused with stem cells from a donor, resulting in a new immune system that eliminates cancer or replaces diseased bone marrow. This study aims to develop new blood tests that predict the onset of acute graft-versus-host disease (aGvHD) and leukaemia relapse, two life-threatening complications that frequently limit the success of treatment. Predictive tests would allow doctors to individualise prophylaxis and intervene early to abort complications before they develop. The study will also create a large collection of clinically annotated blood samples from 300 transplant recipients to support future research and provide a resource to the transplant research community.
Eligibility criteria
Qualifiers
Any recipient of allogeneic haematopoietic stem cell transplantation (HSCT)
Children/infants may participate, there is no age restriction
Patients participating in other clinical trials remain eligible
Disqualifiers
Weight <5kg
Recipients of autologous stem cell transplants
Trial design
Treatments tested in this trial
- Blood sample collection
- Bone marrow aspirate
Treatment groups
No treatment groups listed
Sponsors and collaborators
University of Manchester
Lead sponsor
The Christie NHS Foundation Trust
Collaborator
Source ClinicalTrials.gov